Kisqali (ribociclib) - Novartis
Kisqali: Interim analysis data from P3 NATALEE trial (NCT03701334) for adjuvant HR+, HER2(-) breast cancer in H1 2021 (Novartis) - Jan 29, 2020 - Q4 and FY 2019 Results: Final data from P3 NATALEE trial for adjuvant HR+, HER2(-) breast cancer in 2026 
P3 data
https://www.novartis.com/sites/www.novartis.com/files/q4-2019-investor-presentation.pdf
 
Jan 29, 2020
 
 
4084f750-dfa1-4537-bc16-fe93af6cb30d.jpg